JP Morgan Maintains Overweight on Protagonist Therapeutics, Raises Price Target to $48
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Brian Cheng maintains an Overweight rating on Protagonist Therapeutics (NASDAQ:PTGX) and raises the price target from $39 to $48.
July 25, 2024 | 2:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan analyst Brian Cheng maintains an Overweight rating on Protagonist Therapeutics and raises the price target from $39 to $48.
The raised price target and maintained Overweight rating from a reputable analyst at JP Morgan is likely to positively impact the stock price of Protagonist Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100